{"id":"aurothioglucose","rwe":[{"pmid":"41331379","year":"2026","title":"Targeting protein kinase C signaling cascades in alzheimer's disease: emerging neuroprotective roles of aurothioglucose.","finding":"","journal":"Inflammopharmacology","studyType":"Clinical Study"},{"pmid":"41230800","year":"2025","title":"The zinc finger domains of PARP-1 are selectively and potently inhibited by the Au(I)-based drugs sodium aurothiomalate and aurothioglucose.","finding":"","journal":"FEBS letters","studyType":"Clinical Study"},{"pmid":"41174475","year":"2025","title":"MicroRNA strand ratio disarray promotes temozolomide resistance in glioblastoma.","finding":"","journal":"Cellular & molecular biology letters","studyType":"Clinical Study"},{"pmid":"38570152","year":"2024","title":"Aurothioglucose encapsulated nanoparticles fostered neuroprotection in streptozotocin-induced Alzheimer's disease.","finding":"","journal":"Brain research","studyType":"Clinical Study"},{"pmid":"38206030","year":"2024","title":"Gold(I) ion and the phosphine ligand are necessary for the anti-Toxoplasma gondii activity of auranofin.","finding":"","journal":"Microbiology spectrum","studyType":"Clinical Study"}],"tags":[{"label":"aurothioglucose","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 3A","category":"target"},{"label":"HTR3A","category":"gene"},{"label":"HTR3B","category":"gene"},{"label":"TXNRD1","category":"gene"},{"label":"M01CB04","category":"atc"},{"label":"Active","category":"status"},{"label":"Juvenile rheumatoid arthritis","category":"indication"},{"label":"Rheumatoid arthritis","category":"indication"},{"label":"Antirheumatic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[],"contraindications":["Chronic heart failure","Colitis","Diabetes mellitus","Disease of blood AND/OR blood-forming organ","Disease of liver","Eczema","Eruption of skin","Erythroderma","Fibrosis of lung","Hypertensive disorder","Inflammatory disease of liver","Kidney disease","Leukopenia","Necrotizing enterocolitis in fetus OR newborn","Neutropenic disorder","Pregnancy, function","Severe Debilitation","Sjögren's syndrome","Systemic lupus erythematosus","Thrombocytopenic disorder","Ultraviolet light therapy","Urticaria"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=aurothioglucose","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:56:11.325771+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:56:17.745246+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=aurothioglucose","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:56:18.548384+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Thioredoxin reductase 1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:56:19.126413+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1697725/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:56:19.017006+00:00"}},"allNames":"aureotan","offLabel":[],"synonyms":["aurothioglucose","aureotan","gold thioglucose","thioglucosoaurate"],"timeline":[{"date":"1927-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"brandName":"Aureotan","ecosystem":[{"indication":"Juvenile rheumatoid arthritis","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"celecoxib","slug":"celecoxib","company":"Gd Searle"},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""},{"name":"etodolac","slug":"etodolac","company":"Wyeth Pharms Inc"}],"globalPrevalence":18000000},{"indication":"Rheumatoid arthritis","otherDrugs":[{"name":"abatacept","slug":"abatacept","company":"Bristol Myers Squibb"},{"name":"aceclofenac","slug":"aceclofenac","company":""},{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"}],"globalPrevalence":18000000}],"mechanism":{"target":"5-hydroxytryptamine receptor 3A","targets":[{"gene":"HTR3A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 3A","protein":"5-hydroxytryptamine receptor 3A"},{"gene":"HTR3B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 3B","protein":"5-hydroxytryptamine receptor 3B"},{"gene":"TXNRD1","source":"DrugCentral","target":"Thioredoxin reductase 1, cytoplasmic","protein":"Thioredoxin reductase 1, cytoplasmic"},{"gene":"SQRDL","source":"DrugCentral","target":"Sulfide:quinone oxidoreductase, mitochondrial","protein":"Sulfide:quinone oxidoreductase, mitochondrial"}],"modality":"Small Molecule","drugClass":"aurothioglucose","explanation":"","oneSentence":"","technicalDetail":"Aurothioglucose exerts its anti-inflammatory effects by modulating the activity of the 5-hydroxytryptamine receptor 3A, which is a subtype of serotonin receptor involved in the regulation of immune responses and inflammation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4349","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=aurothioglucose","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=aurothioglucose","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:51:11.323849","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:56:20.931864+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"auranofin","drugSlug":"auranofin","fdaApproval":"1985-05-24","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"aurothioglucose","indications":{"approved":[{"name":"Juvenile rheumatoid arthritis","source":"DrugCentral","snomedId":410795001,"regulator":"FDA","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Rheumatoid arthritis","source":"DrugCentral","snomedId":69896004,"regulator":"FDA","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"}],"offLabel":[{"name":"Felty's syndrome","source":"DrugCentral","drugName":"aurothioglucose","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Psoriasis with arthropathy","source":"DrugCentral","drugName":"aurothioglucose","evidenceCount":18,"evidenceLevel":"moderate"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"auranofin","brandName":"auranofin","genericName":"auranofin","approvalYear":"1985","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01737502","phase":"PHASE1,PHASE2","title":"Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-05-14","conditions":["Extensive Stage Small Cell Lung Carcinoma","Lung Adenocarcinoma","Recurrent Non-Small Cell Lung Carcinoma","Recurrent Small Cell Lung Carcinoma","Squamous Cell Lung Carcinoma","Stage IIIA Non-Small Cell Lung Cancer","Stage IIIB Non-Small Cell Lung Cancer","Stage IV Non-Small Cell Lung Cancer"],"enrollment":29,"completionDate":"2023-04-24"},{"nctId":"NCT06805656","phase":"PHASE2","title":"Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals","status":"NOT_YET_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2025-09-01","conditions":["Hiv","HIV I Infection"],"enrollment":70,"completionDate":"2027-12-31"},{"nctId":"NCT03456700","phase":"PHASE2","title":"Auranofin and Sirolimus in Treating Participants With Ovarian Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2018-03-30","conditions":["Ovarian Serous Tumor","Recurrent Ovarian Carcinoma"],"enrollment":22,"completionDate":"2019-07-31"},{"nctId":"NCT02736968","phase":"PHASE2","title":"Auranofin for Giardia Protozoa","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-06","conditions":["Amoebic Dysentery","Giardiasis"],"enrollment":93,"completionDate":"2021-03-10"},{"nctId":"NCT02770378","phase":"PHASE1,PHASE2","title":"A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2016-11","conditions":["Glioblastoma"],"enrollment":10,"completionDate":"2020-12"},{"nctId":"NCT02961829","phase":"NA","title":"Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2015-07","conditions":["Chronic Infection","HIV"],"enrollment":30,"completionDate":"2020-03"},{"nctId":"NCT01747798","phase":"EARLY_PHASE1","title":"Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-11-02","conditions":["Recurrent Fallopian Tube Cancer","Recurrent Ovarian Epithelial Cancer","Recurrent Primary Peritoneal Cavity Cancer"],"enrollment":10,"completionDate":"2015-04-06"},{"nctId":"NCT02063698","phase":"PHASE2","title":"Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-02-19","conditions":["Pain"],"enrollment":30,"completionDate":"2016-11-11"},{"nctId":"NCT02968927","phase":"PHASE2","title":"TB Host Directed Therapy","status":"UNKNOWN","sponsor":"The Aurum Institute NPC","startDate":"2016-11","conditions":["Tuberculosis"],"enrollment":200,"completionDate":"2020-12"},{"nctId":"NCT02089048","phase":"PHASE1","title":"Auranofin PK Following Oral Dose Administration","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-04-02","conditions":["Amoebiasis"],"enrollment":15,"completionDate":"2015-05-13"},{"nctId":"NCT02126527","phase":"PHASE1","title":"Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2013-08","conditions":["Recurrent Non-small Cell Lung Cancer","Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":0,"completionDate":""},{"nctId":"NCT01419691","phase":"PHASE2","title":"Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2011-09","conditions":["Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma","Leukemia, Prolymphocytic"],"enrollment":15,"completionDate":"2015-09"},{"nctId":"NCT02176135","phase":"PHASE1,PHASE2","title":"Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection","status":"WITHDRAWN","sponsor":"Vaccine and Gene Therapy Institute, Florida","startDate":"","conditions":["HIV"],"enrollment":0,"completionDate":"2017-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000147107","MMSL":"4232","NDDF":"002395","UNII":"2P2V9Q0E78","VUID":"4018804","CHEBI":"CHEBI:2930","VANDF":"4018804","RXNORM":"4980","UMLSCUI":"C0018033","chemblId":"CHEMBL1697725","ChEMBL_ID":"CHEMBL2354773","KEGG_DRUG":"D00991","DRUGBANK_ID":"DB09121","PUBCHEM_CID":"3032577","SNOMEDCT_US":"21880003","MESH_DESCRIPTOR_UI":"D006051"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":247,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"M01CB04","allCodes":["M01CB04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan","pmid":"41331379","title":"Targeting protein kinase C signaling cascades in alzheimer's disease: emerging neuroprotective roles of aurothioglucose.","journal":"Inflammopharmacology"},{"date":"2025 Dec","pmid":"41230800","title":"The zinc finger domains of PARP-1 are selectively and potently inhibited by the Au(I)-based drugs sodium aurothiomalate and aurothioglucose.","journal":"FEBS letters"},{"date":"2025 Oct 31","pmid":"41174475","title":"MicroRNA strand ratio disarray promotes temozolomide resistance in glioblastoma.","journal":"Cellular & molecular biology letters"},{"date":"2024 Jul 1","pmid":"38570152","title":"Aurothioglucose encapsulated nanoparticles fostered neuroprotection in streptozotocin-induced Alzheimer's disease.","journal":"Brain research"},{"date":"2024 Feb 6","pmid":"38206030","title":"Gold(I) ion and the phosphine ligand are necessary for the anti-Toxoplasma gondii activity of auranofin.","journal":"Microbiology spectrum"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:56:20.931864+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}